BBS-Bioactive Bone Substitutes (OHEL:BONEH) Debt-to-Equity : 0.93 (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is BBS-Bioactive Bone Substitutes Debt-to-Equity?

BBS-Bioactive Bone Substitutes's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €0.80 Mil. BBS-Bioactive Bone Substitutes's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €3.95 Mil. BBS-Bioactive Bone Substitutes's Total Stockholders Equity for the quarter that ended in Dec. 2023 was €5.11 Mil. BBS-Bioactive Bone Substitutes's debt to equity for the quarter that ended in Dec. 2023 was 0.93.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for BBS-Bioactive Bone Substitutes's Debt-to-Equity or its related term are showing as below:

OHEL:BONEH' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.93 Med: 1.71 Max: 15.99
Current: 0.93

During the past 9 years, the highest Debt-to-Equity Ratio of BBS-Bioactive Bone Substitutes was 15.99. The lowest was 0.93. And the median was 1.71.

OHEL:BONEH's Debt-to-Equity is ranked worse than
86.38% of 705 companies
in the Medical Devices & Instruments industry
Industry Median: 0.21 vs OHEL:BONEH: 0.93

BBS-Bioactive Bone Substitutes Debt-to-Equity Historical Data

The historical data trend for BBS-Bioactive Bone Substitutes's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BBS-Bioactive Bone Substitutes Debt-to-Equity Chart

BBS-Bioactive Bone Substitutes Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

2.06

0.99

1.71

1.33

0.93

BBS-Bioactive Bone Substitutes Semi-Annual Data
	Dec15	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial											1.71	1.17	1.33	1.46	0.93

Competitive Comparison of BBS-Bioactive Bone Substitutes's Debt-to-Equity

For the Medical Devices subindustry, BBS-Bioactive Bone Substitutes's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BBS-Bioactive Bone Substitutes's Debt-to-Equity Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, BBS-Bioactive Bone Substitutes's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where BBS-Bioactive Bone Substitutes's Debt-to-Equity falls into.

BBS-Bioactive Bone Substitutes Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

BBS-Bioactive Bone Substitutes's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.802	+	3.951)	/	5.108
	=	0.93

BBS-Bioactive Bone Substitutes's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.802	+	3.951)	/	5.108
	=	0.93

BBS-Bioactive Bone Substitutes (OHEL:BONEH) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

BBS-Bioactive Bone Substitutes Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of BBS-Bioactive Bone Substitutes's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

BBS-Bioactive Bone Substitutes (OHEL:BONEH) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » BBS-Bioactive Bone Substitutes PLC (OHEL:BONEH) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

Kiviharjunlenkki 6, Oulu, FIN, 90220

Website

http://www.bbs-artebone.fi

BBS-Bioactive Bone Substitutes PLC is a health technology company, that develops, designs, and manufactures bioactive bone-graft substitute implants. Its ortho-biological product ARTEBONE, which is based on tricalcium phosphate and a natural spectrum of bone proteins has the capability of bone regeneration.

BBS-Bioactive Bone Substitutes (OHEL:BONEH) Headlines

No Headlines